Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Elotuzumab-Iberdomide-Dexamethasone Combination Therapy Activates T and NK Cells within the Immune Microenvironment of Multiple Myeloma Patients

Lucia Y Chen, Michael Amatangelo, Adolfo Aleman, Oliver Van Oekelen, Tania Nevers, Yongliang Sun, William E. Pierceall, Katerina Kappes, Anna Blangiardo, Sundar Jagannath, Cesar Rodriguez, Samir Parekh

Blood (2024) 144 (Supplement 1): 6860.

https://doi.org/10.1182/blood-2024-211651

Published: 2024

Journal Articles

A Phase 2b Study of Selinexor in Combination with Pomalidomide in Patients with Pomalidomide-Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7070.

https://doi.org/10.1182/blood-2024-208473

Published: 2024

Journal Articles

Improving Anti-BCMA CAR-T Functionality with Novel Celmods in Multiple Myeloma

Adolfo Aleman, Leah Grossman, Ariel Kogan Zajdman, Lucia Y Chen, Sidorela Reci, Sundar Jagannath, Samir Parekh

Blood (2024) 144 (Supplement 1): 3259.

https://doi.org/10.1182/blood-2024-201186

Published: 2024

Journal Articles

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Blood (2024) 144 (Supplement 1): 4654.

https://doi.org/10.1182/blood-2024-208308

Published: 2024

Journal Articles

BCMA CART Therapy Failure in Myeloma Is Associated with Immunosuppressive S100A8/9 Overexpression and Can be Ameliorated with Novel Monoclonal Antibodies

Adolfo Aleman, Rongbao Zhao, Leah Grossman, Rahul Sanawar, Srinivas Aluri, Mani Mohindru, Rudra Prasad Dutta, Sidorela Reci, Junia Vieira, David Melnekoff, Alessandro Lagana, Shriya Desai, Sundar Jagannath, Amit Verma, Samir Parekh

Blood (2024) 144 (Supplement 1): 589.

https://doi.org/10.1182/blood-2024-201194

Published: 2024

Journal Articles

Monovalent XBB1.5 Vaccination Augments Humoral and Cellular Immunity to Novel Sars-Cov-2 Variants in Immunocompromised Patients with Multiple Myeloma

Leah Grossman, Adolfo Aleman, Morgan van Kesteren, Sidorela Reci, Charles Gleason, Kseniya Serebryakova, Katerina Kappes, Hayley Jackson, Jessica Nardulli, Hyun Min Kang, Jacob Mischka, Komal Srivastava, Lubbertus CF Mulder, Sundar Jagannath, Florian Krammer, Viviana Simon, Samir Parekh

Blood (2024) 144 (Supplement 1): 4691.

https://doi.org/10.1182/blood-2024-203556

Published: 2024

Journal Articles

Delayed Neutrophil Recovery Following BCMA-Directed CAR-T Correlates with Poor Outcomes and Is Associated with a Cytokine Signature of Persistent Inflammation and T Cell Checkpoint Activation

Zachary M Avigan, Saoirse Bodnar, Darren Pan, Adolfo Aleman, Joshua Richter, Larysa J Sanchez, Cesar Rodriguez, Adriana Rossi, Shambavi Richard, Hearn Jay Cho, Sundar Jagannath, Samir Parekh, Santiago Thibaud

Blood (2024) 144 (Supplement 1): 3329.

https://doi.org/10.1182/blood-2024-202725

Published: 2024

Journal Articles

Combined PD-1 and Tim-3 Blockade Improves the in Vitro Anti-Myeloma Activity of T Cells of Patients on Talquetamab

Blood (2024) 144 (Supplement 1): 357.

https://doi.org/10.1182/blood-2024-204929

Published: 2024

Journal Articles

A Phase 2b Study of Selinexor in Combination with Carfilzomib, Daratumumab, or Pomalidomide in Patients with Multiple Myeloma Relapsing on Current Therapy

Blood (2023) 142 (Supplement 1): 6714.

https://doi.org/10.1182/blood-2023-187011

Published: 2023

Journal Articles

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Lucia Y Chen, Oliver Van Oekelen, Michael Amatangelo, Tracy T. Chow, Bhaskar Upadhyaya, Alessandro Lagana, Geoffrey Kelly, Seunghee Kim-Schulze, Adolfo Aleman, Antonina Kurtova, Sarah Gooding, Sundar Jagannath, Erin Flynt, Anita K. Gandhi, Udo Oppermann, Anjan Thakurta, Samir Parekh

Blood (2023) 142 (Supplement 1): 4686.

https://doi.org/10.1182/blood-2023-187748

Published: 2023

Journal Articles

Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 93.

https://doi.org/10.1182/blood-2023-186395

Published: 2023

Journal Articles

Cellular Mechanisms Associated with Suboptimal Immune Responses to Sars-Cov-2 Bivalent Booster Vaccination in Patients with Multiple Myeloma

Adolfo Aleman, Morgan Van Kesteren, Ariel Kogan Zajdman, Komal Srivastava, Lucia Y Chen, Bhaskar Upadhyaya, Jessica Nardulli, Kseniya Serebryakova, Katerina Kappes, Hayley Jackson, Charles Gleason, Oliver Van Oekelen, Carlos Cordon-Cardo, Ania Wajnberg, Florian Krammer, Miriam Merad, Sundar Jagannath, Viviana Simon, Samir Parekh

Blood (2023) 142 (Supplement 1): 1984.

https://doi.org/10.1182/blood-2023-187260

Published: 2023

Journal Articles

Teclistamab Demonstrates Clinical Activity in Real-World Patients Ineligible for the Pivotal Majestec-1 Trial

Beth Gordon, Lindsay Fogel, Gaurav Varma, Mateo Mejia Saldarriaga, Jaeil Ahn, Adolfo Aleman, Jessica Caro, Xiaoyi Chen, Jorge Monge, Harsh Parmar, David Kaminetzky, Tibor Moskovits, David S. Siegel, Gareth J. Morgan, Ruben Niesvizky, Noa Biran, Faith E. Davies

Blood (2023) 142 (Supplement 1): 4741.

https://doi.org/10.1182/blood-2023-181304

Published: 2023

Journal Articles

Gut Microbiota Diversity and Composition Is Associated with High-Risk Myeloma

Rena Feinman, Ariel Aptekmann, Iriana Colorado, Samuel Roy, Katelyn Quino, Noreen Ahmed, Adolfo Aleman, Rashmi Unawane, Joshua Zenreich, Alana Barofsky, Kashish Bhatt, Michele L. Donato, Noa Biran, David S. Siegel

Blood (2023) 142 (Supplement 1): 3294.

https://doi.org/10.1182/blood-2023-190108

Published: 2023

Journal Articles

A Phase 1/2 Study of Carfilzomib, Iberdomide and Dexamethasone (KID) in Patients with Newly Diagnosed Transplant-Eligible Multiple Myeloma

Blood (2023) 142 (Supplement 1): 2022.

https://doi.org/10.1182/blood-2023-189907

Published: 2023

Journal Articles

Immune Dynamics Associated with Patient Outcomes Identified By Multimodal Single-Cell Analysis in Multiple Myeloma Patients Receiving Talquetamab Monotherapy

Blood (2023) 142 (Supplement 1): 1927.

https://doi.org/10.1182/blood-2023-185308

Published: 2023

Journal Articles

Timing of Vaccination Impacts Serological Response to COVID-19 Myeloma Patients after BCMA-Targeted CAR T

Blood (2023) 142 (Supplement 1): 3350.

https://doi.org/10.1182/blood-2023-184409

Published: 2023

Journal Articles

Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

Blood (2023) 141 (7): 756–765.

https://doi.org/10.1182/blood.2022017848

Published: 2023

Includes: Supplemental data

Journal Articles

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Blood (2022) 140 (Supplement 1): 614–616.

https://doi.org/10.1182/blood-2022-165646

Published: 2022

Journal Articles

Gut Microbiome Composition Is Associated with Engraftment Syndrome in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 4843–4844.

https://doi.org/10.1182/blood-2022-168934

Published: 2022

NARROW

Elotuzumab-Iberdomide-Dexamethasone Combination Therapy Activates T and NK Cells within the Immune Microenvironment of Multiple Myeloma Patients

A Phase 2b Study of Selinexor in Combination with Pomalidomide in Patients with Pomalidomide-Refractory Multiple Myeloma

Improving Anti-BCMA CAR-T Functionality with Novel Celmods in Multiple Myeloma

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

BCMA CART Therapy Failure in Myeloma Is Associated with Immunosuppressive S100A8/9 Overexpression and Can be Ameliorated with Novel Monoclonal Antibodies

Monovalent XBB1.5 Vaccination Augments Humoral and Cellular Immunity to Novel Sars-Cov-2 Variants in Immunocompromised Patients with Multiple Myeloma

Delayed Neutrophil Recovery Following BCMA-Directed CAR-T Correlates with Poor Outcomes and Is Associated with a Cytokine Signature of Persistent Inflammation and T Cell Checkpoint Activation

Combined PD-1 and Tim-3 Blockade Improves the in Vitro Anti-Myeloma Activity of T Cells of Patients on Talquetamab

A Phase 2b Study of Selinexor in Combination with Carfilzomib, Daratumumab, or Pomalidomide in Patients with Multiple Myeloma Relapsing on Current Therapy

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Multiple Myeloma

Cellular Mechanisms Associated with Suboptimal Immune Responses to Sars-Cov-2 Bivalent Booster Vaccination in Patients with Multiple Myeloma

Teclistamab Demonstrates Clinical Activity in Real-World Patients Ineligible for the Pivotal Majestec-1 Trial

Gut Microbiota Diversity and Composition Is Associated with High-Risk Myeloma

A Phase 1/2 Study of Carfilzomib, Iberdomide and Dexamethasone (KID) in Patients with Newly Diagnosed Transplant-Eligible Multiple Myeloma

Immune Dynamics Associated with Patient Outcomes Identified By Multimodal Single-Cell Analysis in Multiple Myeloma Patients Receiving Talquetamab Monotherapy

Timing of Vaccination Impacts Serological Response to COVID-19 Myeloma Patients after BCMA-Targeted CAR T

Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Gut Microbiome Composition Is Associated with Engraftment Syndrome in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only